David Kolesky
Principal at MPM BioImpact
Boston, Massachusetts
Overview
Work Experience
Principal
2023 - Current
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Principal
2021 - 2023
Senior Associate
2020 - 2021
Associate
2018 - 2020
Fellow
2018 - 2018
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Co-Founder and Chief Innovation Officer
2020 - 2023
Montai Health is unlocking the power of nature with digital technologies to create Anthromolecule medicines to treat and preempt chronic disease. Our ambition is to develop safer, accessible, pathway modulating solutions with the potential to slow and potentially halt disease progression.
Acting Chief Scientific Officer
2020 - 2022
Co-Founder
2017 - 2023
Senda Biosciences is developing new categories of life-changing medicines. With unique insights into the trillions of interspecies molecular connections in the human body, we can create novel treatments for human disease — with applications across a wide variety of therapeutic areas.
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Raised $309,000,000.00 from Alexandria Venture Investments, Samsung Life Science Fund, State of Michigan Retirement System, Stage 1 Ventures, Mayo Clinic, Qatar Investment Authority, Bluwave Capital, Longevity Vision Fund, Flagship Pioneering and Partners Investment.
Head of iLabs
2020 - 2021
Invaio Sciences is a multi-platform technology company that unlocks the potential of our planet’s interdependent natural systems to solve pressing agriculture, nutrition & environmental challenges.
Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.
Raised $138,900,000.00 from K2 HealthVentures.
Technology Development Fellow
2017 - 2018
Developing technologies related to organ and tissue engineering for clinical translation.
Postdoctoral Fellow - Jennifer Lewis Lab
2016 - 2016
Developing materials and 3D printing methods for building for building vascularized tissues for in vitro models and, ultimately, tissue replacement. Utilizing principles of microfluidics and bioengineering toward applications in kidney, bone, and blood vessel models.
Ph.D. Materials Science and Engineering - Jennifer Lewis Lab
2012 - 2016
3D Bioprinting of vascularized tissue constructs: I developed a 3D printing approach to create vasculature within cell-laden tissue structures that could be used for drug screening or tissue engineering. Through collaborations with pharmaceutical companies, we are exploring these avenues.
Student
2014 - 2014
Selected to participate in Harvard Graduate Business Club's Mini-MBA program ('14). Summer program aimed at exposing non-business students to business school concepts and taught using Harvard's Case Method.
PHD Student
2010 - 2012
Developed conductive inks for printed and wearable electronics. Co-invented high-throughput microfluidic printheads for 3D printing increasing total print speed 64x.
Racheff Teaching Fellow
2012 - 2012
Teaching Assistant for MSE 405 - Microstructure Determination. Ran and organized X-Ray Diffraction and Raman Spectroscopy labs graded lab reports, exams, and homework.